Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients
Table 3
Invasive and noninvasive tests for advanced liver disease in First Nations and Non-First Nations patients with nonalcoholic fatty liver disease.
First Nations
Non-First Nations
Variable
%
%
Liver histology
Liver biopsy performed
11
33.3
85
18.9
0.045
NASH
4
36.4
24
28.2
0.84
Grade 0–2 inflammation
11
100
77
90.6
0.63
Grade 3-4 inflammation
0
0
3
3.5
Stage 0–2 fibrosis
11
100
77
90.6
0.63
Stage 3-4 fibrosis
0
0
8
9.4
APRI
APRI at baseline
0.67 ± 0.8
0.75 ± 1.2
0.63
APRI at follow-up
0.51 ± 0.3
0.50 ± 0.4
0.97
NAFLD fibrosis score
0.74
Predictive of F0–F2 fibrosis
20
60.6
299
66.6
Indeterminate score
10
30.3
112
24.9
Predictive of F3-F4 fibrosis
3
9.1
38
8.5
Results represent mean ± SD. From Angulo et al. [42]: the NAFLD fibrosis score, a noninvasive system that identifies liver fibrosis in patients with NAFLD. NASH: nonalcoholic steatohepatitis; APRI: AST-to-Platelet Ratio Index; NAFLD: nonalcoholic fatty liver disease.